Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma

Blood

Volumn 101, Issue 5, 2003, Pages 1718-1726

  Rousseau, Raphaël F ^a   Haight, Ann E ^b   Hirschmann Jax, Charlotte ^b   Yvon, Eric S ^b   Rill, Donna R ^b   Mei, Zhuyong ^b   Smith, Susan C ^b   Inman, Shannon ^b   Cooper, Kristine ^b   Alcoser, Pat ^b   Grilley, Bambi ^b   Gee, Adrian ^b   Popek, Edwina ^b   Davidoff, Andrew ^b   Bowman, Laura C ^b   Brenner, Malcolm K ^b   Strother, Douglas ^b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; LYMPHOTACTIN; TUMOR VACCINE;

ADVANCED CANCER; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BONE PAIN; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; NATURAL KILLER CELL; NEUROBLASTOMA; PANNICULITIS; PRIORITY JOURNAL;

EID: 0037372307     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2493     Document Type: Article

References (40)

1. Jaffee EM, Lazenby A, Meurer J, et al. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother Emphasis Tumor Immunol. 1995;18:1-9.
2. Barth RJ, Mule JJ. Cytokine gene transfer into tumor cells: animal models. In: Brenner MK, Moen RC, eds. Gene Therapy in Cancer. New York, NY: Marcel Dekker; 1996:73-94.
3. Rousseau R, Hirschmann-Jax C, Takahashi S, Brenner M. Cancer vaccines. Hematol Oncol Clin North Am. 2001;15:741-773.
4. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther. 1994;5:153-164.
5. Maass G, Schmidt W, Berger M, et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci U S A. 1995;92:5540-5544.
6. Ostrand-Rosenberg S, Gunther V, Armstrong T, et al. Immunologic targets for the gene therapy of cancer. In: Lattime E, Gerson S, eds. Gene Therapy of Cancer. San Diego, CA: Academic Press; 1999:33-44.
7. Tanaka T, Kanai F, Okabe S, et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. 1996;56:1341-1345.
8. Dilloo D, Bacon K, Holden W; et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996;2:1090-1095.
9. Kennedy J, Kelner GS, Kleyensteuber S, et al. Molecular cloning and functional characterization of human lymphotactin. J Immunol. 1995;155:203-209.
10. Kelner GS, Kennedy J, Bacon KB, et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science. 1994;266:1395-1399.
11. Ju DW, Tao Q, Cheng DS, et al. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Ther. 2000;7;329-338.
12. Cerdan C, Serfling E, Olive D. The C-class chemokine, lymphotactin, impairs the induction of Th1-type lymphokines in human CD4(+) T cells. Blood. 2000;96:420-428.
13. Hedrick JA, Zlotnik A. Lymphotactin. Clin Immunol Immunopathol. 1998;87:218-222.
14. Emtage PC, Wan Y, Hitt M, et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther. 1999;10:697-709.
15. Xia DJ, Zhang WP, Zheng S, et al. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Gene Ther. 2002;9:592-601.
16. + T cells and neutrophils expressing XCR1 receptor. J Immunol. 2001;167:57-65.
17. + T cells and intratumoral lymphotactin transgene expression. Cancer Res. 2002;62:2043-2051.
18. Bowman LC, Grossmann M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998;9:1303-1311.
19. Cheung NK. Immunotherapy: neuroblastoma as a model. Pediatr Clin North Am. 1991;38:425-441.
20. Shamamian P, Mancini M, Kawakami Y, Restifo NP, Rosenberg SA, Topalian SL. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest. Cancer Immunol Immunother. 1994;39:73-83.
21. Zhao XJ, Cheung NK. GD2 oligosaccharide: target for cytotoxic T lymphocytes. J Exp Med. 1995;182:67-74.
22. Main EK, Lampson LA, Hart MK, Kornbluth J, Wilson DB. Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol. 1985;135:242-246.
23. Evans A, Main E, Zier K, et al. The effects of gamma interferon on the natural killer and tumor cells of children with neuroblastoma: a preliminary report. Cancer. 1989;64:1383-1387.
24. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci U S A. 1993;90:2774-2778.
25. Coze C, Aalto-Setala K, Brenner M, Chiang Y. Characteristics and immunomodulatory properties of human neuroblastoma cells after retrovirus-mediated gene transfer of the cytokine genes IL-2 and IFN-gamma. Transgenics. 1995;1:585-595.
26. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci U S A. 1989;86:9456-9460.
27. Sadanaga N, Nagoshi M, Lederer JA, Joo HG, Eberlein TJ, Goedegebuure PS. Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells. J Immunother. 1999;22:315-323.
28. Giancarlo B, Silvano S, Albert Z, Mantovani A, Allavena P. Migratory response of human natural killer cells to lymphotactin. Eur J Immunol. 1996;26:3238-3241.
29. Main EK, Monos DS, Lampson LA. IFN-treated neuroblastoma cell lines remain resistant to T cell-mediated allo-killing, and susceptible to non-MHC-restricted cytotoxicity. J Immunol. 1988;141:2943-2950.
30. Bianchi AC, Heslop HE, Veys P, et al. Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. Br J Haematol. 1989;73:468-474.
31. Hank JA, Robinson RR, Surfus J, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res. 1990;50:5234-5239.
32. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 1991;77:1859-1870.
33. Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med. 1999;189:803-810.
34. Favrot MC, Combaret V, Goillot E, et al. Expression of leucocyte adhesion molecules on 66 clinical neuroblastoma specimens. Int J Cancer. 1991;48:502-510.
35. Fabian I, Kravtsov V, Elis A, et al. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy. Leukemia. 1994;8:1379-1384.
36. Rivoltini L, Viggiano V, Spinazze S, et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2: role of interleukin 5. Int J Cancer. 1993;54:8-15.
37. Hung K, Hayashi R, Lafond-WalkerA, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188:2357-2368.
38. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science. 1992;257:548-551.
39. Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother. 1998;47:1-12.
40. Kushner BH, Kramer K, Cheung NK. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol. 1999;17:3221-3225.